Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: An understanding of the incidence and outcomes of Clostridium difficile infection (CDI) in the United States can inform investments in prevention and treatment interventions.

Objective: To quantify the incidence of CDI and its associated hospital length of stay (LOS) in the United States using a systematic literature review and meta-analysis.

Data Sources: MEDLINE via Ovid, Cochrane Library Databases via Wiley, Cumulative Index of Nursing and Allied Health Complete via EBSCO Information Services, Scopus, and Web of Science were searched for studies published in the United States between 2000 and 2019 that evaluated CDI and its associated LOS.

Study Selection: Incidence data were collected only from multicenter studies that had at least 5 sites. The LOS studies were included only if they assessed postinfection LOS or used methods accounting for time to infection using a multistate model or compared propensity score-matched patients with CDI with control patients without CDI. Long-term-care facility studies were excluded. Of the 119 full-text articles, 86 studies (72.3%) met the selection criteria.

Data Extraction And Synthesis: Two independent reviewers performed the data abstraction and quality assessment. Incidence data were pooled only when the denominators used the same units (eg, patient-days). These data were pooled by summing the number of hospital-onset CDI incident cases and the denominators across studies. Random-effects models were used to obtain pooled mean differences. Heterogeneity was assessed using the I2 value. Data analysis was performed in February 2019.

Main Outcomes And Measures: Incidence of CDI and CDI-associated hospital LOS in the United States.

Results: When the 13 studies that evaluated incidence data in patient-days due to hospital-onset CDI were pooled, the CDI incidence rate was 8.3 cases per 10 000 patient-days. Among propensity score-matched studies (16 of 20 studies), the CDI-associated mean difference in LOS (in days) between patients with and without CDI varied from 3.0 days (95% CI, 1.44-4.63 days) to 21.6 days (95% CI, 19.29-23.90 days).

Conclusions And Relevance: Pooled estimates from currently available literature suggest that CDI is associated with a large burden on the health care system. However, these estimates should be interpreted with caution because higher-quality studies should be completed to guide future evaluations of CDI prevention and treatment interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991241PMC
http://dx.doi.org/10.1001/jamanetworkopen.2019.17597DOI Listing

Publication Analysis

Top Keywords

cdi
12
united states
12
cdi associated
12
incidence data
12
patients cdi
12
studies
10
incidence
8
incidence outcomes
8
clostridium difficile
8
prevention treatment
8

Similar Publications

infection and antibiotic prescribing at a regional hospital in Australia: a case-control study.

Antimicrob Steward Healthc Epidemiol

September 2025

National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT, Australia.

Background: infections (CDI) increased at a large, regional hospital in New South Wales, Australia, in 2021, coinciding with an increase at hospitals Australia wide. We aimed to investigate the association between antibiotic prescribing practices and hospital-acquired CDI at the hospital to inform antimicrobial stewardship (AMS) programs.

Methods: We conducted a retrospective case-control study for the period July 1, 2018, and June 30, 2022.

View Article and Find Full Text PDF

Bacterial volatile organic compounds (VOCs) have been investigated as non-invasive approaches for the diagnosis of infectious diseases. Here, we aimed to explore potential diagnostic markers by profiling VOCs in cultures of unique clinical Clostridioides difficile (C. difficile) isolates and stool samples from pediatric patients with C.

View Article and Find Full Text PDF

Overview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.

Children: Fully vaccinated coverage in Australian children in 2022 was 0.

View Article and Find Full Text PDF

Shigellosis in South East Metropolitan Melbourne, 1 January 2022 - 31 March 2023.

Commun Dis Intell (2018)

February 2025

Faculty of Medicine, Nursing and Health Science, Monash University, Victoria; South East Public Health Unit, Monash Health, Victoria.

Introduction: Shigella is a notifiable condition in Victoria under the Public Health and Wellbeing Act. Since 24 October 2022, the South East Public Health Unit (SEPHU) has been managing these notifications for the south east region of Melbourne.

Aim: This study aimed to determine the demographics and risk factors for acquisition of shigellosis cases in the SEPHU catchment.

View Article and Find Full Text PDF

Australian Gonococcal Surveillance Program, 1 January to 31 March 2025.

Commun Dis Intell (2018)

February 2025

The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Au

The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin.

View Article and Find Full Text PDF